Novo Nordisk CEO Mike Doustdar said on Monday as many as 1.5 million patients in the U.S. may be using compounded versions of ...

What motivated the shift into the veterinary space? Topelius: Actually, we started with veterinary applications. When we founded the company, our first application areas w ...

CEO Mike Doustdar shared the figure Monday at the J.P. Morgan Healthcare Conference, saying compounded versions have gained ...

When endocrinologist Dan Bessesen, MD, looked online and saw how easy it would be for him to purchase a weight loss drug from ...

Compounded semaglutide is a medication that’s custom-made by a compounding pharmacy. It contains the active ingredient semaglutide, which is a glucagon-like peptide-1 (GLP-1) receptor agonist.

The runaway popularity of GLP-1 medications like Ozempic and Wegovy for weight loss and diabetes management led to a nationwide shortage that lasted more than a year—and created the perfect conditions ...

Drugmakers Eli Lilly and Novo Nordisk have been sued in Texas by a compounding pharmacy that alleges they are illegally ...

Structure CEO warns compounded weight-loss drugs could threaten new obesity treatments as the company prepares to bring its ...

In these cases, compounded drugs are filling a specific need. While many GLP-1s were on the FDA’s shortage list, as of earlier this year, the FDA has removed them, meaning that the compounding of ...

Lawsuit alleges anti-competitive conduct designed to suppress lawful compounding pharmaceuticals and limit patient choice ...

Compounding pharmacy sues Eli Lilly and Novo Nordisk alleging antitrust violations to restrict compounded GLP-1 medication access and limit competition.